Pentracor is a medical device company that has developed a breakthrough innovation for the treatment of acute myocardial infarction. Our first product on the German market is PentraSorb® CRP and has attracted much attention since the completion of a landmark clinical trial. Pentracor has a research and development pipeline in several therapeutic areas based on our unique expertise in immunology.
In heart attack and stroke, the C-reactive protein (CRP) leads to an increase of the primary damage. Further, the severity of rheumatic diseases is often determined by the amount of CRP.
The CRP adsorber (PentraSorb® CRP) is CE-marked. The corresponding Quality management system certificate according to EN ISO 13485 and the EC Certificate of Conformity in accordance with Directive 93/42/EEC are available.